Kersten Dirk 4

What Happened

• Kersten Dirk, a director of Dyne Therapeutics (DYN), sold a total of 688,788 shares in several open-market disposals on March 9–10, 2026 for aggregate proceeds of approximately $13.15 million. The individual transactions reported: 177,690 shares at a weighted avg $17.72 ($3.15M), 9,482 shares at $18.21 ($172.7K), 219,758 shares at $19.32 ($4.25M), and 281,858 shares at $19.80 ($5.58M). These were sales (not purchases), which are typically routine dispositions rather than a bullish signal.

Key Details

• Transaction dates: March 9, 2026 and March 10, 2026. Form filed on March 11, 2026 (appears timely).
• Aggregate shares sold: 688,788; aggregate proceeds: ~$13,149,314.
• Price details / ranges: reported as weighted averages; per-footnote ranges were $17.50–$18.21, $17.595–$18.59, $18.61–$19.605, and $19.61–$20.03 for the various blocks.
• Footnote: the March 9 sale was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. on Nov 11, 2025.
• Ownership notes: the shares are held directly by ForDyne B.V., an entity jointly owned by Forbion funds. Kersten is a partner/committee member in the related management entities and may be deemed to have voting/dispositive power over the shares; he disclaims beneficial ownership except for any pecuniary interest.
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context

• These are open-market sales by an entity-linked insider and include at least one sale under a pre-established 10b5-1 plan, which typically indicates scheduled disposals rather than trades based on new company information. For retail investors, purchases often signal conviction more than routine sales; this filing documents a sizable institutional-linked liquidation but does not on its own indicate company performance or insider sentiment.